Under construction – not a live service

Skip to content

Frontlight Research

Institution

Jiangsu Province Hospital

Nanjing, ChinahealthcareWebsite

Also known as: First Affiliated Hospital of Nanjing Medical University · 江苏省人民医院

263running trials
68closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
NCT07866612· Source
Recruiting
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
NCT07789184· Phase 3· Source
Not yet recruiting
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861· Phase 3· Source
Not yet recruiting
A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
NCT07796477· Phase 2· Source
Not yet recruiting
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
NCT07920939· Phase 3· Source
Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· Phase 3· Source
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
NCT07876557· Phase 2· Source
Not yet recruiting
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
NCT07844187· Phase 1/2· Source
Recruiting
A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With TRUPULSE™ Generator in Persistent Atrial Fibrillation
NCT07845682· Source
Recruiting
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
NCT07323095· Phase 2· Source
Recruiting
Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia
NCT07874451· Source
Not yet recruiting
Treatment Strategy for Patients With RA-ILD
NCT07643038· Phase 4· Source
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Source
Not yet recruiting
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188· Phase 3· Source
Not yet recruiting
A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
NCT07782086· Source
Not yet recruiting
Sphere-9 PAF China Study
NCT07789925· Source
Not yet recruiting
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
NCT07831395· Phase 2· Source
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Source
Not yet recruiting
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
NCT07799649· Source
Not yet recruiting
Sino-Russian Comparison of Outcomes After Proximal Gastrectomy With Double-Tract Reconstruction
NCT07800819· Source
Recruiting
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667· Phase 2· Source
Recruiting
A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
NCT07743944· Source
Not yet recruiting
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601· Source
Not yet recruiting
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
NCT07765524· Phase 1/2· Source
Recruiting
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
NCT07640295· Phase 1/2· Source
Recruiting
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
NCT07719556· Phase 2· Source
Recruiting
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186· Phase 2· Source
Recruiting
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
NCT07609823· Phase 2· Source
Not yet recruiting
A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
NCT07669740· Phase 2· Source
Recruiting
CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
NCT07615348· Phase 2· Source
Not yet recruiting
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0
NCT07682415· Phase 2· Source
Recruiting
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
NCT07622836· Source
Recruiting
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
NCT07589569· Phase 2· Source
Recruiting
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
NCT07608978· Phase 2· Source
Not yet recruiting
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757· Phase 3· Source
Recruiting
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
NCT07671378· Phase 2· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Source
Recruiting
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
NCT07646639· Phase 2· Source
Recruiting
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
NCT07607275· Phase 4· Source
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372· Source
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· Phase 3· Source
Not yet recruiting
Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
NCT07523789· Source
Not yet recruiting
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
NCT07014878· Phase 1· Source
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Source
Recruiting
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
NCT07464756· Phase 2· Source
Recruiting
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
NCT07558863· Phase 4· Source
Recruiting
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
NCT07498478· Phase 2· Source
Not yet recruiting
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479· Phase 3· Source
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
NCT07436949· Phase 1/2· Source
Not yet recruiting
A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)
NCT07471165· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Gastric and esophageal cancer27 recruiting
Lung cancer18 recruiting
Chronic lymphocytic leukaemia14 recruiting
Colorectal cancer13 recruiting
Metastatic breast cancer11 recruiting
Liver and biliary tract cancer10 recruiting
Prostate cancer10 recruiting
Multiple myeloma7 recruiting
Pancreatic cancer7 recruiting
Triple-negative breast cancer7 recruiting
Atrial fibrillation6 recruiting
Bladder cancer6 recruiting
Coronary artery disease6 recruiting
Childhood cancers4 recruiting
Follicular lymphoma4 recruiting
Head and neck cancer4 recruiting
Hepatitis B4 recruiting
High blood pressure4 recruiting
Mantle cell lymphoma4 recruiting
Type 2 diabetes4 recruiting
Kidney cancer3 recruiting
Lupus (SLE)3 recruiting
Type 1 diabetes3 recruiting
Acute lymphoblastic leukaemia2 recruiting
Acute myeloid leukemia2 recruiting
Amyloidosis2 recruiting
Asthma2 recruiting
Chronic myeloid leukaemia2 recruiting
COPD2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Fatty liver disease (MASLD/MASH)2 recruiting
Heart failure2 recruiting
Obesity2 recruiting
Ovarian cancer2 recruiting
Primary biliary cholangitis2 recruiting
Psoriasis2 recruiting
Psoriatic arthritis2 recruiting
Stroke2 recruiting
Alzheimer disease1 recruiting
Chronic kidney disease1 recruiting
Crohn's disease1 recruiting
Myelodysplastic syndromes1 recruiting
Myeloproliferative neoplasms1 recruiting
Neuroendocrine tumours1 recruiting
Pulmonary arterial hypertension1 recruiting
Rheumatoid arthritis1 recruiting
Sarcoma1 recruiting
Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· Phase 3· Source
Withdrawn
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT06866080· Early phase 1· Source
Completed
Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia
NCT07052838· Phase 3· Source
Completed
A Clinical Study of Mass Balance of [14C]HRS-7535
NCT06819488· Phase 1· Source
Completed
The Efficacy and Mechanism of SMA+M1 Repetitive Transcranial Magnetic Stimulation on Freezing of Gait in PD
NCT06415682· Source
Completed
Brachial Versus Femoral Access for Carotid Artery Stenting
NCT06557135· Source
Completed
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
NCT06549816· Phase 1· Source
Completed
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
NCT06884670· Phase 2· Source
Completed
A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）
NCT06561841· Phase 2· Source
Completed
Screening of Biomarkers and Related Mechanisms for RIX
NCT06700863· Source
Completed
Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%
NCT06321094· Source
Completed
Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail
NCT06108596· Phase 2· Source
Terminated
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
NCT05828589· Phase 1· Source
Completed
Effect of HIIT on Cardiopulmonary Function After PCI in Patients With Coronary Heart Disease
NCT06575569· Source
Completed
Evaluation of ClearLLab LS Screening Panel
NCT05819762· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Source
Completed
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
NCT05673993· Phase 3· Source
Completed
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)
NCT05810948· Phase 2· Source
Completed
Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid Size
NCT06516796· Source
Completed
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
NCT05520177· Phase 3· Source
Completed
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT05522231· Phase 2/3· Source
Completed
Curative Effect and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation on Sleep Disorders of PD
NCT05806736· Source
Completed
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
NCT05445908· Phase 2· Source
Completed
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
NCT05918107· Phase 2· Source
Completed
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
NCT05900882· Phase 2· Source
Withdrawn
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL
NCT05259813· Phase 1· Source
Completed
Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer
NCT07015489· Phase 2· Source
Completed
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
NCT05051891· Phase 3· Source
Completed
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
NCT05029921· Phase 4· Source
Terminated
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
NCT05336721· Phase 2· Source
Completed
A Study of Vedolizumab in Adults in Real-World Practice
NCT04872491· Source
Completed
Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction
NCT04944706· Phase 2· Source
Completed
Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging
NCT05045872· Phase 1· Source
Completed
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
NCT05054751· Phase 3· Source
Completed
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04939142· Phase 3· Source
Terminated
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04808570· Phase 1/2· Source
Terminated
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551053· Phase 3· Source
Terminated
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551066· Phase 3· Source
Completed
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
NCT04796623· Phase 2· Source
Completed
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04657302· Phase 1· Source
Completed
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
NCT04643470· Phase 2· Source
Completed
New Model of Integrated Care of Older Patients With Atrial Fibrillation in Rural China
NCT04622514· Source
Completed
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
NCT06048913· Phase 2· Source
Completed
Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma
NCT04570410· Phase 2· Source
Completed
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
NCT04435626· Phase 3· Source
Completed
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
NCT04830826· Source
Completed
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04202003· Phase 1/2· Source
Completed
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
NCT04238715· Phase 2· Source
Completed
Factors Determine the Feasibility and Surgical Margin Quality of Sublobar Resection for Non-small Cell Lung Cancer?
NCT07005401· Source
Completed
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT04126681· Phase 2· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Liver and biliary tract cancer125 works · 12 trials
Gastric and esophageal cancer97 works · 36 trials
Lung cancer94 works · 36 trials
Atrial fibrillation64 works · 7 trials
Colorectal cancer64 works · 19 trials
Bladder cancer35 works · 8 trials
Kidney cancer35 works · 4 trials
Pancreatic cancer34 works · 8 trials
Triple-negative breast cancer33 works · 16 trials
Glioblastoma28 works · 0 trials
Fatty liver disease (MASLD/MASH)24 works · 2 trials
Thyroid cancer23 works · 0 trials
Diffuse large B-cell lymphoma23 works · 5 trials
Psoriasis20 works · 1 trials
Metastatic breast cancer19 works · 24 trials
Neuroendocrine tumours15 works · 1 trials
Diabetic eye disease15 works · 0 trials
Chronic lymphocytic leukaemia13 works · 26 trials
Pulmonary arterial hypertension10 works · 2 trials
Mesothelioma9 works · 1 trials
Follicular lymphoma5 works · 8 trials
Chronic myeloid leukaemia5 works · 3 trials
Mantle cell lymphoma5 works · 7 trials
Sjögren's disease4 works · 1 trials

Institution data: ROR 04py1g812 (CC0-1.0)Updated 10 Nov 2026

Report an error